Protagen counts on Scienion Technology
(PresseBox) - Protagen AG today announced that Scienion AG will produce protein microarray batches for the clinical validation of the proprietary biomarker panels of Protagen. The batch sizes will comprise more than 1000 arrays.
Additionally, both companies plan to jointly evaluate new platforms for multiplex analytics and to co-develop novel approaches up to proof-ofconcept levels under a strategic partnership.
"For the multicenter, international clinical validation studies of our multiplex diagnostic markers for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer it is essential to ensure a consistently high statistical reliability for diagnostic conclusions. Scienion's sciFLEXARRAYER technology - worldwide leading in nanodispensing - allows the manufacturing of protein microarray batches each with more than 3500 single proteins in highest quality and reproducibility", comments Dr. Peter Schulz-Knappe, CSO of Protagen AG. "Thereby, we can realize the needed consistency in quality and properties throughout three stages: from spot to spot, from array to array and from batch to batch."
"We are very pleased to welcome Protagen as a customer and partner for joint developments. The leading position of Protagen in providing high quality content for protein microarrays, and the UNIarray® concept for the development and validation of multiplex markers offers Scienion the possibility to perform feasibility studies close to the market and thus to demonstrate Scienion's capacity and efficiency to new customers from the diagnostics and pharma industry", states Dr. Holger Eickhoff, CEO of Scienion AG.
About Scienion
Scienion AG provides systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, Scienion offers a unique technology portfolio that has been consequently expanded over one decade. Scienion provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by its versatility, precision and robustness. The company is a renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. Scienion's dispensers allow for contactfree and precise drop spotting in the pico- to nano-liter range and are optimally suited for microarray based analytics - as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various carriers.
The company operates from two sites, Dortmund and Berlin.
Protagen AG (www.protagen.de) is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Protagen AG (www.protagen.de) is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.
Datum: 19.04.2011 - 02:58 Uhr
Sprache: Deutsch
News-ID 1022939
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Dortmund
Phone:
Kategorie:
Healthcare & Medical
Anmerkungen:
Diese Pressemitteilung wurde bisher 319 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Protagen counts on Scienion Technology
"
steht unter der journalistisch-redaktionellen Verantwortung von
Protagen AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
